KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EPS (Weighted Average and Diluted) (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 16 years of EPS (Weighted Average and Diluted) data on record, last reported at $7.87 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 2.96% year-over-year to $7.87; the TTM value through Dec 2025 reached $41.48, up 8.22%, while the annual FY2025 figure was $41.48, 8.19% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $7.87 in Q4 2025 per REGN's latest filing, down from $13.59 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $27.97 in Q2 2021 and bottomed at -$14.07 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is $9.51, with a median of $8.89 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 267.52% in 2021, then plummeted 73.29% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $14.33 in 2021, then tumbled by 198.19% to -$14.07 in 2022, then skyrocketed by 172.49% to $10.2 in 2023, then fell by 20.49% to $8.11 in 2024, then decreased by 2.96% to $7.87 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $7.87 in Q4 2025, $13.59 in Q3 2025, and $12.75 in Q2 2025.